← All trials
NCT04931342
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 7, 2021
- Primary completion
- Aug 15, 2024
- Completion date
- Mar 31, 2026
- First posted
- Jun 18, 2021
- Last posted
- Nov 16, 2021
- Enrollment
- 200
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- RocheLead sponsor
- European Network for Gynaecological Oncological TrialCollaborator
- RocheStudy director
- GOG Foundation, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.